ArticlePLOS digital health2026
Explainable artificial intelligence for personalized prognosis in pancreatic cancer: A nationwide study from Taiwan.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is highly aggressive with poor outcomes; current artificial intelligence (AI) prognostic models often lack interpretability and underutilize large-scale data. This study develops an explainable AI prognostic model for pancreatic cancer survival using Taiwan's national registry data, aiming to identify key prognostic factors, their interactions, non-linear relationships, and patient-specific survival variability. We analyzed 8,864 pancreatic cancer cases diagnosed between 2013 and 2021 from the Taiwan Cancer Registry. We developed three classes of prognostic models using regression-based, machine learning, and deep learning methods. The models were evaluated using nested cross-validation and time-dependent metrics, with Shapley additive explanations enhancing interpretability. XGBoost outperformed random survival forest and deep learning models in predicting pancreatic cancer survival. Key determinants included surgery, histological type, chemotherapy, tumor stage, and their interactions. Adenocarcinoma was associated with the highest mortality risk, whereas acinar cell and neuroendocrine carcinomas had lower risks (hazard ratios 0.768 and 0.660, respectively, vs adenocarcinoma). Chemotherapy showed the greatest mortality risk reduction in adenocarcinoma, while surgery was most strongly associated with reduced mortality in neuroendocrine tumors and adenocarcinoma, particularly in early-stage disease. The mortality reduction associated with chemotherapy increased in advanced stages and with age, plateauing around 65 years. Mortality risk rose faster with age in neuroendocrine carcinoma. Non-linear relationships emerged for age, smoking duration, and BMI: mortality increased gradually (0.69% per year) before age 65, rapidly afterward (2.41% per year); risk increased with longer smoking duration but plateaued between 10 and 30 years; and BMI exhibited a U-shaped risk, lowest at 26. This study demonstrates the potential of explainable AI for predicting pancreatic cancer survival by identifying key prognostic factors, nonlinear relationships, interactions, and patient-level variability, thereby revealing substantial heterogeneity in prognosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.